Skip to main content

Hydralazine Disease Interactions

There are 6 disease interactions with hydralazine.

Major

Hydralazine (applies to hydralazine) bone marrow suppression

Major Potential Hazard, Low plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Hydralazine may rarely cause blood dyscrasias at recommended dosages. Reduction in hemoglobin, red cell count, agranulocytosis, leukopenia, and purpura have been reported. Therapy with hydralazine should be administered cautiously in patients with these preexisting conditions and if such abnormalities develop during the course of therapy, treatment should be discontinued. Monitoring blood counts should be considered for those patients at higher risk.

References

  1. Koch-Weser J (1976) "Hydralazine." N Engl J Med, 295, p. 320-3
  2. Orenstein AA, Yakulis V, Eipe J, Costea N (1977) "Immune hemolysis due to hydralazine." Ann Intern Med, 86, p. 450-1
  3. Widerlov E, Karlman I, Storsater J (1980) "Hydralazine-induced neonatal thrombocytopenia." N Engl J Med, 303, p. 1235
  4. Freestone S, Ramsay LE (1982) "Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus." Br Med J, 285, p. 1536-7
  5. Macleod WN (1983) "Anaemia in the hydrallazine-induced lupus syndrome." Scott Med J, 28, p. 181-2
  6. Harrison BD, Laidlaw ST, Reilly JT (1995) "Fatal aplastic anaemia associated with lisinopril." Lancet, 346, p. 247-8
  7. (2001) "Product Information. Apresoline (hydralazine)." Ciba-Geigy Pharmaceuticals
View all 7 references
Major

Hydralazine (applies to hydralazine) coronary artery disease

Major Potential Hazard, High plausibility. Applicable conditions: Ischemic Heart Disease

The use of hydralazine is contraindicated in patients with coronary artery disease. Reflex tachycardia may commonly occur. Palpitations and chest pain have also been reported. Myocardial infarction has been associated with the use of hydralazine.

References

  1. Koch-Weser J (1976) "Hydralazine." N Engl J Med, 295, p. 320-3
  2. Laslett LJ, DeMaria AN, Amsterdam EA, Mason DT (1978) "Hydralazine-induced tachycardia and sodium retention in heart failure: hemodynamic and symptomatic correlation by prazosin therapy." Arch Intern Med, 138, p. 819-20
  3. Packer M, Meller J, Medina N, et al. (1981) "Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure." Am J Cardiol, 48, p. 939-46
Major

Hydralazine (applies to hydralazine) lupus erythematosus

Major Potential Hazard, High plausibility.

The use of hydralazine has been associated with the development of lupus erythematosus and lupus-like syndromes, as well as exacerbation of the disease. Hydralazine therapy should be withdrawn in patients experiencing worsening of preexisting lupus. Monitoring complete blood counts, and antinuclear antibody titers before and during prolonged therapy is recommended.

References

  1. Hahn BH, Sharp GC, Irvin WS, et al. (1972) "Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus." Ann Intern Med, 76, p. 365-74
  2. Carey RM, Coleman M, Feder A (1973) "Pericardial tamponade: a major presenting manifestation of hydralazine-induced lupus syndrome." Am J Med, 54, p. 84-7
  3. Perry HM (1973) "Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis." Am J Med, 54, p. 58-72
  4. Blumenkrantz N, Christiansen AH, Ullman S, Asboe-Hansen G (1974) "Hydralazine-induced lupoid syndrome." Acta Med Scand, 195, p. 443-9
  5. Weinstein J (1978) "Hypocomplementemia in hydralazine-associated systemic lupus erythematosus." Am J Med, 65, p. 553-6
  6. Freestone S, Ramsay LE (1982) "Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus." Br Med J, 285, p. 1536-7
  7. Macleod WN (1983) "Anaemia in the hydrallazine-induced lupus syndrome." Scott Med J, 28, p. 181-2
  8. Ihle BU, Whitworth JA, Dowling JP, Kincaid-Smith P (1984) "Hydralazine and lupus nephritis." Clin Nephrol, 22, p. 230-8
  9. Cameron HA, Ramsay LE (1984) "The lupus syndrome induced by hydralazine: a common complication with low dose treatment." Br Med J, 289, p. 410-12
  10. Naparstek Y, Kopolovic J, Tur-Kaspa R, Rubinger D (1984) "Focal glumerulonephritis in the course of hydralazine-induced lupus syndrome." Arthritis Rheum, 27, p. 822-5
  11. Shapiro KS, Pinn VW, Harrington JT, Levey AS (1984) "Immune complex glomerulonephritis in hydralazine-induced SLE." Am J Kidney Dis, 3, p. 270-4
  12. Cush JJ, Goldings EA (1985) "Southwestern internal medicine conference: drug-induced lupus: clinical spectrum and pathogenesis." Am J Med Sci, 290, p. 36-45
  13. Innes A, Rennie JA, Cato GR (1986) "Drug-induced lupus caused by very-low-dose hydralazine." Br J Rheumatol, 25, p. 225-31
  14. Darwaza A, Lamey P-J, Connell JM (1988) "Hydrallazine-induced Sjogren's syndrome." Int J Oral Maxillofac Surg, 17, p. 92-3
  15. Sturman SG, Kumararatne D, Beevers DG (1988) "Fatal hydralazine-induced systemic lupus erythematosus." Lancet, 12/03/88, p. 1304
  16. Fleming MG, Bergfeld WF, Tomecki KJ, et al. (1989) "Bullous systemic lupus erythematosus." Int J Dermatol, 28, p. 321-6
  17. Ramsey-Goldman R, Franz T, Solano FX, Medsger TA (1990) "Hydralazine induced lupus and sweet's syndrome: report and review of the literature." J Rheumatol, 17, p. 682-4
  18. Lunde PK, Frislid K, Hansteen V (1977) "Disease and acetylation polymorphism." Clin Pharmacokinet, 2, p. 182-97
  19. Timbrell JA, Facchini V, Harland SJ, Mansilla-Tinoco R (1984) "Hydralazine-induced lupus: is there a toxic metabolic pathway?" Eur J Clin Pharmacol, 27, p. 555-9
  20. (2001) "Product Information. Apresoline (hydralazine)." Ciba-Geigy Pharmaceuticals
  21. Pirmohamed M (1996) "Hydralazine-induced lupus: yet another autoantibody! triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine - comment." Hum Exp Toxicol, 15, p. 361-2
View all 21 references
Major

Hydralazine (applies to hydralazine) valvular heart disease

Major Potential Hazard, High plausibility.

The use of hydralazine is contraindicated in patients with mitral valvular rheumatic heart disease.

References

  1. (2001) "Product Information. Apresoline (hydralazine)." Ciba-Geigy Pharmaceuticals
Moderate

Hydralazine (applies to hydralazine) cerebral vasculopathy

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cerebral Vascular Disorder

The vasodilatory effects of hydralazine may aggravate cerebral vasculopathy. Therapy with hydralazine should be administered cautiously in patients with cerebral vasculopathy.

References

  1. Koch-Weser J (1976) "Hydralazine." N Engl J Med, 295, p. 320-3
  2. (2001) "Product Information. Apresoline (hydralazine)." Ciba-Geigy Pharmaceuticals
Moderate

Hydralazine (applies to hydralazine) renal dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glomerulonephritis

The use of hydralazine has been associated with the development of glomerulonephritis. Hydralazine should be used with caution in patients with advanced renal damage and these patients may require a lower dose. Renal function should be monitored and supported as required.

References

  1. (2001) "Product Information. Apresoline (hydralazine)." Ciba-Geigy Pharmaceuticals

Hydralazine drug interactions

There are 399 drug interactions with hydralazine.

Hydralazine alcohol/food interactions

There is 1 alcohol/food interaction with hydralazine.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.